Nexell Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Begins European launch of next-generation, fully-automated Isolex 300i positive/negative stem cell selection system. Nexell plans to submit a PMA supplement this year to FDA for the hardware and software modifications to the Isolex 300i positive selection system currently marketed in the U.S. Phase III trials are currently under way